Tomomi Kashiwada

Randomized, Phase II Study of Trastuzumab Beyond Progression in Patients With HER2-Positive Advanced Gastric or Gastroesophageal Junction Cancer: WJOG7112G (T-ACT Study)

Akitaka Makiyama, Yasutaka Sukawa, Tomomi Kashiwada et al. · Journal of Clinical Oncology · 2020 · 185 citations

Propensity Score Analysis of Regorafenib Versus Trifluridine/Tipiracil in Patients with Metastatic Colorectal Cancer Refractory to Standard Chemotherapy (REGOTAS): A Japanese Society for Cancer of the Colon and Rectum Multicenter Observational Study

Toshikazu Moriwaki, Shota Fukuoka, Hiroya Taniguchi et al. · The Oncologist · 2017 · 104 citations · Full text

Re-evaluation of HER2 status in patients with HER2-positive advanced or recurrent gastric cancer refractory to trastuzumab (KSCC1604)

Hiroshi Saeki, Eiji Oki, Tomomi Kashiwada et al. · European Journal of Cancer · 2018 · 97 citations

Her2 Status, Surgical Oncology, Oncology +6

A randomized phase II study of weekly paclitaxel ± trastuzumab in patients with HER2-positive advanced gastric or gastro-esophageal junction cancer refractory to trastuzumab combined with fluoropyrimidine and platinum: WJOG7112G (T-ACT).

Akitaka Makiyama, Kosuke Sagara, Junji Kawada et al. · Journal of Clinical Oncology · 2018 · 36 citations

Breast Oncology, Esophageal Cancer, Gastrointestinal Oncology +13

Multicenter phase II study of SOX plus trastuzumab for patients with HER2+ metastatic or recurrent gastric cancer: KSCC/HGCSG/CCOG/PerSeUS 1501B

Satoshi Yuki, Katsunori Shinozaki, Tomomi Kashiwada et al. · Cancer Chemotherapy and Pharmacology · 2019 · 27 citations

Gastrointestinal Oncology, Recurrent Gastric Cancer, Medicine +5